BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15165635)

  • 21. Rapid oral loading of extended release divalproex in patients with acute mania.
    Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D
    Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
    Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
    Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
    McCabe PH; Michel NC; McNew CD; Lehman EB
    Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid clearance in children with epilepsy.
    Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
    J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
    Dutta S; Zhang Y; Selness DS; Lee LL; Williams LA; Sommerville KW
    Epilepsy Res; 2002 Mar; 49(1):1-10. PubMed ID: 11948003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers.
    Glue P; Fang A; Gandelman K; Klee B
    Am J Ther; 2006; 13(5):418-22. PubMed ID: 16988537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
    Pierre-Louis SJ; Brannegan RT; Evans AT
    Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
    Apostol G; Lewis DW; Laforet GA; Robieson WZ; Fugate JM; Abi-Saab WM; Saltarelli MD
    Headache; 2009 Jan; 49(1):45-53. PubMed ID: 19040679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
    Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
    J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divalproex sodium vs. valproic acid: drug utilization patterns, persistence rates and predictors of hospitalization among VA patients diagnosed with bipolar disorder.
    Iqbal SU; Cunningham F; Lee A; Wang S; Hamed A; Miller DR; Ren X; Kazis L
    J Clin Pharm Ther; 2007 Dec; 32(6):625-32. PubMed ID: 18021341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.
    Almeida L; Minciu I; Nunes T; Butoianu N; Falcão A; Magureanu SA; Soares-da-Silva P
    J Clin Pharmacol; 2008 Aug; 48(8):966-77. PubMed ID: 18508949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.